Seroprevalence of hepatitis B infection and active immunization in Ecuadorian Amazonian indigenous people: A cross-sectional study


  • Natalia Romero-Sandoval School of Medicine, Universidad Internacional del Ecuador, Quito, Ecuador. Red GRAAL, Barcelona, Spain
  • Andres Flores Faculty of Medicine, Universidad Autónoma de Barcelona, Barcelona, Catalunya, Spain. Red GRAAL, Barcelona, Spain
  • Nicole Mora-Bowen School of Medicine, Universidad Internacional del Ecuador, Quito, Ecuador.
  • Lino Arisqueta Facultad de Ciencias de la Salud, Universidad Internacional SEK Ecuador, Quito, Pichincha, Ecuador
  • Cristina Moreno School of Medicine, Universidad Internacional del Ecuador, Quito, Ecuador
  • Richard Douce Spectrum/Lakeland Hospital, Saint Joseph, Michigan, United State of America
  • Miguel Martín Faculty of Medicine, Universidad Autónoma de Barcelona, Barcelona, Catalunya, Spain. Red GRAAL, Barcelona, Spain



hepatitis b antibodies, hepatitis b antigens, Health of Indigenous Peoples, Epidemiology


Introduction: Hepatitis B surveillance is crucial. We proposed to describe the seroprevalence of Hepatitis B infection and the associated factors among Ecuadorian Amazonia communities. Outline: A serologic cross-sectional study was carried out in subjects over two years old. We classified seropositivity according to the Centers of Diseases Control criteria and recorded sex, age, temporary migration, sometime Hepatitis B in their life, and previous vaccination. Results: Out of 215 participants, 50.0%, 8.8%, 1.9%, and 1.4% were susceptible, immune due to natural infection, chronic infection, and early acute HBV infection, respectively. Of the 8 people who reported having ever been diagnosed with Hepatitis B, none showed chronic or acute infection and one was positive for immunity due to the vaccine. HBsAg was found in 3.3% (95% IC 0.9-7.0) and was higher among those who migrate 7.7% (p-value 0.04). 16.3% (95% CI 11.6-21.4) was immune due to HBV vaccination. Among the 58 participants who declared having received the vaccine, 20.7% presented post-vaccine immunity. Implications: Participants who should have benefited from the vaccination campaign (susceptible) are those with the lowest immune response due to vaccination. To assessing the burden of viral hepatitis in people living in marginalized areas and guide preventive measures is mandatory.


Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis [Internet]. 2010 Jul [cited 2020 Oct 10];14(1):1–21. Available from:

Cabezas C, Braga W. Hepatitis B Virus and Delta Infection: Special Considerations in the Indigenous and Isolated Riverside Populations in the Amazon Region. Clin Liver Dis [Internet]. 2020 Sep [cited 2020 Oct 10];16(3):117–22. Available from:

Graham S, Guy RJ, Cowie B, Wand HC, Donovan B, Akre SP, et al. Chronic hepatitis B prevalence among Aboriginal and Torres Strait Islander Australians since universal vaccination: a systematic review and meta-analysis. BMC Infect Dis [Internet]. 2013 Aug [cited 2020 Oct 10];13:403. Available from:

De La Hoz F, Durán MM, lglesias Gamarra A, Velandia MP, Rojas MC. Factores de riesgo en la transmisión de la hepatitis B en la amazonia colombiana. Biomedica [Internet]. 1992 Jul [cited 2020 Oct 10];12(1):5–9. Available from:

Blackwell AD, Snodgrass JJ, Madimenos FC, Sugiyama LS. Life history, immune function, and intestinal helminths: Trade-offs among immunoglobulin E, C-reactive protein, and growth in an Amazonian population. Am J Hum Biol [Internet]. 2010 Dez [cited 2020 Oct 10];22(6):836–48. Available from:

Jokisch BD, McSweeney K. Assessing the potential of indigenous-run demographic/health surveys: the 2005 Shuar survey, Ecuador. Human Ecology [Internet]. 2011 Jul [cited 2020 Oct 10];39(5):683–98. Available from:

Brunette GW. CDC Yellow Book 2018: health information for international travel. Oxford: University Press; 2017.

Ropero AM, Danovaro-Holliday MC, Andrus JK. Progress in vaccination against hepatitis B in the Americas. J Clin Virol [Internet]. 2005 Jul [cited 2020 Oct 10];34:14–9. Available from:

World Health Organization, World Health Organization, Global Hepatitis Programme. Global hepatitis report, 2017 [Internet]. 2017 [cited 2020 Oct 11]. Available from:

Jokisch BD, McSweeney K. Informe sobre los Resultados del Diagnóstico de la Situacíon de Salud y de los Servicios de Salud de las Nacionalidades Shuar y Achuar FICSH-FIPSE-FINAE 2005 [Internet]. University of Ohio, Ohio State University; 2007. Available from:

Centers for Disease Control and Prevention M. Updated CDC Recommendations for the Management of Hepatitis B Virus–Infected Health-Care Providers and Students. 2012 Juy; 61(RR-3).

World Health Organization. Global Hepatitis Report. WHO/CDS/CSR/LYO/2002.2:Hepatitis B [Internet]. Department of Communicable Diseases Surveillance and Response; 2002. Available from:;jsessionid=BDA0D1EE747


Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet [Internet]. 2015 Jul [cited 2020 Oct 10];386(10003):1546–55. Available from:

Chang MS, Nguyen MH. Epidemiology of hepatitis B and the role of vaccination. Best Pract Res Clin Gastroenterol [Internet]. 2017 Jan [cited 2020 Oct 10];31(3):239–47. Available from:

Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infec Dis [Internet]. 2016 Feb [cited 2020 Oct 10];16(12):1399–408. Available from:

Garcia D, Porras A, Mendoza AR, Alvis N, Navas MC, De La Hoz F, et al. Hepatitis B infection control in Colombian Amazon after 15 years of hepatitis B vaccination. Effectiveness of birth dose and current prevalence. Vaccine [Internet]. 2018 Jul [cited 2020 Oct 10];36(19):2721–6. Available from:

Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et al. Hepatitis B virus burden in developing countries. World J Gastroenterol [Internet]. 2015 Nov [cited 2020 Oct 10];21(42):11941–53. Available from:

De la Hoz F, Perez L, de Neira M, Hall AJ. Eight years of hepatitis B vaccination in Colombia with a recombinant vaccine: factors influencing hepatitis B virus infection and effectiveness. Intern J Infec Dis [Internet]. 2008 Jul [cited 2020 Oct 10];12(2):183–9. Available from:



Como Citar

Romero-Sandoval, N., Flores, A., Mora-Bowen, N., Arisqueta, L., Moreno, C., Douce, R., & Martín, M. (2023). Seroprevalence of hepatitis B infection and active immunization in Ecuadorian Amazonian indigenous people: A cross-sectional study. Revista Prevenção De Infecção E Saúde, 8(1).